Doomed: EU soy-cholesterol health claims after appeal fails


- Last updated on GMT

Related tags Health claims Soybean European union

EU soy-cholesterol health claims after appeal fails
The European Food Safety Authority (EFSA) appears to have nailed shut the door for soy-cholesterol reducing health claims in the European Union, after dismissing a series of formal objections to its third rejection of the bean’s cholesterol-lowering capacity.

Most of the comments from both academia and industry criticised EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) for casting aside a 23-study strong meta-analysis focused on the potential of soy protein isolate to reduce cholesterol levels, but the NDA was not swayed to alter its opinion.

“The Panel assessed all 23 studies individually and considered that four of the RCTs (randomised clinical trials) did not allow conclusions to be drawn on the effects of ISP on blood cholesterol concentrations owing to inadequate methodology or insufficient reporting,”​ it wrote.

“Most of the remaining RCTs were at high risk of bias, owing to methodological limitations in the analysis, and/or had poor reporting of the data, and differences in the results obtained between trials appeared to be unrelated to the dose of ISP used, sample size or study duration.”

No reliable evidence

The NDA said while four RCTs showed a significant cholesterol-lowering effect, 14 did not, and therefore the meta-analysis, “would not provide any reliable evidence additional to that provided by the individual studies, and could give rise to risk of a biased outcome.”

It added: “Results from the other 11 published meta-analyses (Anderson et al., 1995; Anderson and Bush, 2011; Balk et al., 2005; Harland and Haffner, 2008; Hooper et al., 2008; Jenkins et al., 2010; Reynolds et al., 2006; Taku et al., 2007; Weggemans and Trautwein, 2003; Zhan and Ho, 2005; Zhuo et al., 2004) submitted with the application were also excluded from consideration for substantiation of the claim as the meta-analyses were either not designed to assess the effects of ISP, but rather of isoflavones or of soy protein from different sources, or contained studies which were considered by the applicant as not pertinent to the claim.”

The Soya Protein Association (SPA), the European Vegetable Protein Federation (EUVEPRO) and the European Natural Soyfood Manufacturers Association were the joint submitters of the article 14 disease risk reduction claim under the EU 2006 nutritition and health claims regulation (NHCR).

They submitted comments along with academics including Professor Penny M. Kris-Etherton, David J.A. Jenkins, Arash Mirrahimi, Kristie Srichaikul, Laura Chiavaroli, Livia S.A. Augustin, John L. Sievenpiper, Russell J. de Souza and Cyril W.C. Kendall.

The claims are likely to be banned across the EU within a year.

Soy-cholesterol claims are affirmed by authorities in Brazil, the US, the Philippines, Japan, the UK, South Africa, Indonesia, Korea, Malaysia and Turkey.

The NDA response can be found here.

Related news

Show more

Related products

show more

Women's Health For All Life Stages

Women's Health For All Life Stages

Content provided by Gencor | 29-May-2024 | White Paper

SPINS' recent industry trends analysis shows that women's health is finally getting its due after years of being overlooked in favor of men's...

Related suppliers

1 comment


Posted by Kenneth Tremble,

SOY caused stones in my left kidney. People suffering health problems do not know that SOY is causing them. State Health Depts. here in Australia do not care. It was when I read that Soy is toxic and back in the past it was only used in paint and paint thinners. The Soy producers know this.

Report abuse

Follow us


View more